Current Report Filing (8-k)
30 December 2021 - 9:29AM
Edgar (US Regulatory)
0001321834
false
0001321834
2021-12-29
2021-12-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 29, 2021
MyMD
Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
MyMD
Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 623
Baltimore, MD 21205
(Address of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (856) 848-8698
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
Registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, no par value per share
|
|
MYMD
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On
December 29, 2021, MyMD Pharmaceuticals, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual
Meeting”). At the Company’s Annual Meeting, holders of
the Company’s voting securities with a total aggregate voting power of 31,371,678 votes were present
in person or represented by proxy. The matters submitted for a vote and the related results are set forth below.
|
(1)
|
Election
of six directors to serve on our board of directors to serve for a term of one year or until their successors are elected and qualified:
|
Nominee
|
|
Votes
For
|
|
Votes
Withheld
|
|
Broker
Non-Votes
|
Chris
Chapman
|
|
26,548,186
|
|
58,587
|
|
4,764,905
|
Craig
Eagle
|
|
26,599,709
|
|
7,064
|
|
4,764,905
|
Christopher
C. Schreiber
|
|
26,557,751
|
|
49,022
|
|
4,764,905
|
Joshua
Silverman
|
|
24,859,416
|
|
1,747,357
|
|
4,764,905
|
Jude
Uzonwanne
|
|
26,597,722
|
|
9,051
|
|
4,764,905
|
Bill
J. White
|
|
26,138,800
|
|
467,973
|
|
4,764,905
|
The
terms of the Company’s directors were scheduled to expire at the Annual Meeting, and the Board nominated all six directors for
re-election at the Annual Meeting. At the Annual Meeting, Dr. Chris Chapman, Dr. Craig Eagle, Mr. Christopher C. Schreiber, Mr. Joshua
Silverman, Mr. Jude Uzonwanne, and Mr. Bill J. White were elected as directors of the Board to serve for a term expiring at the Company’s
2022 annual meeting of stockholders.
|
(2)
|
Ratification
of the appointment of Morison Cogen LLP as our independent registered public accounting firm for the fiscal year ending December
31, 2021:
|
Votes
For
|
|
Votes
Against
|
|
Votes
Abstaining
|
31,345,919
|
|
22,163
|
|
3,596
|
For
more information about the foregoing proposals, see the Company’s definitive proxy statement for the Annual Meeting, filed with
the Securities and Exchange Commission on November 22, 2021, as supplemented, the relevant portions of which are incorporated
herein by reference.
The
results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
|
|
Description
|
104
|
|
Cover
Page Interactive Data File (formatted as Inline XBRL)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MyMD
PHARMACEUTICALS, INC.
|
|
|
|
Date:
December 29, 2021
|
By:
|
/s/
Chris Chapman
|
|
|
Chris
Chapman, M.D.
|
|
|
President
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024